APA

Pozniak A., Flamm J., Antinori A., Bloch M., Ward D., Berenguer J., Cote P., Andreatta K., Garner W., Szwarcberg J., Nguyen-Cleary T., McColl D. J. & Piontkowsky D. (20180511). Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. : HIV clinical trials.

Chicago

Pozniak Anton, Flamm Jason, Antinori Andrea, Bloch Mark, Ward Douglas, Berenguer Juan, Cote Pierre, Andreatta Kristen, Garner William, Szwarcberg Javier, Nguyen-Cleary Thai, McColl Damian J and Piontkowsky David. 20180511. Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. : HIV clinical trials.

Harvard

Pozniak A., Flamm J., Antinori A., Bloch M., Ward D., Berenguer J., Cote P., Andreatta K., Garner W., Szwarcberg J., Nguyen-Cleary T., McColl D. J. and Piontkowsky D. (20180511). Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. : HIV clinical trials.

MLA

Pozniak Anton, Flamm Jason, Antinori Andrea, Bloch Mark, Ward Douglas, Berenguer Juan, Cote Pierre, Andreatta Kristen, Garner William, Szwarcberg Javier, Nguyen-Cleary Thai, McColl Damian J and Piontkowsky David. Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. : HIV clinical trials. 20180511.